Amonafide CAS: 69408-81-7 is an antineoplastic drug used for the treatment of various types of cancer. It is a DNA intercalating agent that belongs to the class of anthraquinone derivatives. Amonafide is also known under the chemical name 2-amino-9-(2-morpholin-4-ylethyl)-6-acridinone hydrochloride. The molecular formula of Amonafide is C18H20N4O2.HCl, and its molecular weight is 360.84 g/mol.
Top ten keywords for Amonafide include:
Synonyms for Amonafide include AS1413, NSC-308847, and 2-amino-9-(2-morpholin-4-ylethyl) acridin-4-one hydrochloride.
Health benefits of this product:
Amonafide has shown promising results in the treatment of various types of cancer, including ovarian, breast, lung, and blood cancers. It works by intercalating into the DNA of cancer cells, damaging the DNA strands, and inhibiting the replication of cancer cells. Amonafide has also exhibited lower toxicity than other chemotherapy drugs, making it a possible alternative for cancer patients.
Potential effects:
Amonafide has exhibited potential antitumor effects in various types of cancer cell lines. It has been shown to induce cell death in cancer cells by blocking DNA synthesis and replication, which ultimately leads to tumor cell cytotoxicity. In preclinical trials, amonafide has also been shown to improve the efficacy of radiation therapy.
Product mechanism:
Amonafide acts as a DNA intercalating agent, and its mode of action involves intercalating into the DNA of cancer cells. The intercalation causes the DNA strands to separate, leading to damage to the DNA and inhibition of DNA replication. This ultimately leads to cell death, resulting in cytotoxicity and tumor regression.
Safety:
Amonafide has been shown to have manageable safety profiles with no significant toxicities observed in clinical trials. However, like other chemotherapy drugs, it can damage healthy cells in the body, leading to side effects like nausea, diarrhea, fatigue, and hair loss. Patients undergoing chemotherapy with amonafide should be monitored closely for any adverse effects.
Side effects:
The most common side effects of Amonafide include gastrointestinal upset, such as nausea, vomiting, and diarrhea. Patients can also experience fatigue, hair loss, and decreased blood cell count. Other side effects like mucositis and allergic reactions are less common.
Dosing information:
The dosage for amonafide depends on several factors, including the type of cancer being treated, the patient's health status, and other medications in use. The standard dose for amonafide is between 300-400 mg/m2 administered every 3-4 weeks as an intravenous infusion.
Conclusion:
In conclusion, Amonafide CAS: 69408-81-7 is a promising drug for the treatment of various types of cancer. It works by intercalating into the DNA of cancer cells, causing damage to the DNA and inhibiting the replication of cancer cells. Amonafide has shown lower toxicity than other chemotherapy drugs, making it a potential alternative for cancer patients. It also exhibits potential antitumor effects and may improve the efficacy of radiation therapy. However, like other chemotherapy drugs, amonafide can cause side effects, and patients should be closely monitored during treatment. Further research and clinical trials may be necessary to better understand the full potential of amonafide's effects on cancer treatment
